bioMérieux – First-Half 2019 Results

• Organic sales growth of 5.5% for first-half 2019:
  
  • €1,275 million in sales
  • Up 9.1% as reported
• As expected, growth accelerated in the second quarter, up to 7.4% at constant exchange rates and scope of consolidation, buoyed by a robust performance in molecular biology
• Increase in contributive operating income before non-recurring items, up to €198 million or 15.5% of sales, in line with annual targets
• 2019 targets confirmed:
  
  • Organic growth in sales of between 7.0% and 8.5% at constant exchange rates and scope of consolidation
  • Contributive operating income before non-recurring items of between €385 million and €400 million at current exchange rates

Alexandre Mérieux, Chairman and Chief Executive Officer, said: “bioMérieux performed well in the first half of 2019, in line with its targets, with business picking up pace in the second quarter. The Group was able to deliver solid financial results for the period, and we are confident that we will meet our operating income targets for the year as a whole.”